93 articles
A large real-world study finds GLP-1 drugs cut anxiety and depression risk vs. older weight-loss meds — but tirzepatide raises insomnia flags.
New review shows where fat is stored — not total body weight — determines atherogenic dyslipidemia and heart disease risk.
A new review argues that combining GLP-1 receptor agonists with structured exercise and dietary support preserves muscle and delivers lasting fat loss.
From CAR T-cell senolytics to AI-designed reprogramming factors, 2025 delivered landmark advances in aging science.
A Nature Aging perspective asks whether GLP-1 receptor agonists like semaglutide are true anti-aging therapies or simply metabolic drugs.
A comprehensive 2025 review framework matches GLP-1 agonists, tirzepatide, and other AOMs to specific obesity phenotypes, complications, and life stages.
A landmark review synthesizes 12 hallmarks of aging, emerging gerotherapeutics, and a new three-tier clinical care model to shift medicine from disease treatment to aging prevention.
GLP-1 receptor agonists used for obesity may deliver an unexpected reproductive benefit: higher testosterone and better sperm.
Analysis of 2,242 NAFLD clinical trials reveals GLP-1 receptor agonists dominate the pipeline, with semaglutide and liraglutide leading the charge.
A landmark 21-year trial finds diet and exercise interventions cut multimorbidity risk by 21% in prediabetic adults — metformin showed no such benefit.
Geroscience pioneer Dr Nir Barzilai explains how intervening in aging biology — not individual diseases — may be medicine's biggest leap.
GLP-1 receptor agonists used for weight loss may also restore male reproductive hormones and improve sperm parameters.
